OnCore Login

Return to Trial Database

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Status

Currently Enrolling

Cancer Type(s)

Bladder

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-GU21-551 being conducted in.
Icahn School of Medicine at Mount Sinai
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278